poisar

Stocks · News reference

AstraZeneca And Daiichi Sankyo Dose First Patient In Phase 3 TROPION-Urothelial04 Trial Of Datroway In Muscle-Invasive Urothelial Cancer

Aug 26, 2026, 11:11 AMBenzinga Newsdesk

The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab monotherapy

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AZN
Source
benzinga
Observed
Aug 26, 2026, 11:11 AM
Checked
Aug 26, 2026, 11:11 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 4:11 PMNa

    SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

    Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.

    Read original at zacks-investment-research
    SMMTAZNMRK